SCHEDULE: Brian and Barbara Pratt Disclose 7.4% Stake in NeuroOne

Brian and Barbara Pratt have filed a Schedule 13G disclosing a 7.4% beneficial ownership stake in NeuroOne Medical Technologies Corporation.

Summary

• Brian and Barbara Pratt jointly own 627,344 shares of NeuroOne Medical Technologies Corporation common stock.
• This holding represents a 7.4% interest in the company.
• The ownership percentage is calculated based on 8,420,999 shares outstanding following a 1-for-6 reverse stock split effective April 15, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of ownership, reflecting a standard regulatory requirement rather than a change in company strategy or performance.

Positives

• The filing indicates a significant long-term investment interest from the reporting persons.
• The reporting persons have certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer.

Negatives

• The disclosure follows a significant 1-for-6 reverse stock split, which often reflects past downward pressure on the share price.

Risks

• The company is subject to the volatility associated with medical technology development and regulatory approval processes.
• The recent reverse stock split may impact liquidity and investor perception.

Future Outlook

The filing does not provide forward-looking guidance regarding the company's operations, but confirms the reporting persons' intent to hold the shares as a passive investment.

Management Comments

• The reporting persons certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by individual investors in small-cap medical technology firms often signal confidence in the company's underlying intellectual property or clinical pipeline despite recent corporate restructuring like reverse splits.

Comparison to Industry Standards

• The 7.4% stake is a standard threshold for significant minority interest in micro-cap medical device companies.
• The use of a 1-for-6 reverse split is a common mechanism for companies in this sector to maintain compliance with exchange listing requirements.

Stakeholder Impact

• Shareholders may view the disclosure of a 7.4% stake as a sign of stability in the shareholder base.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes in their percentage of ownership.

Key Dates

Keywords

NeuroOne Medical Technologies, Schedule 13G, Brian Pratt, Barbara Pratt, Beneficial Ownership, Reverse Stock Split